Apimeds pharmaceuticals us, inc. announces closing of initial public offering

Hopewell, new jersey, may 12, 2025 (globe newswire) -- apimeds pharmaceuticals us, inc. (nyse american: apus) (“apimeds” or the “company”), a clinical stage biopharmaceutical company that is in the process of developing apitox, an intradermally administered bee venom-based toxin which potentially exhibits diverse therapeutic effects, today announced the closing of its initial public offering (the “offering”) of 3,375,000 shares of common stock at a public offering price of $4.00 per share. the shares began trading on the nyse american on may 9, 2025, under the symbol “apus.”
APUS Ratings Summary
APUS Quant Ranking